Genzyme: Delivering Hope

Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with many established products and services helping patients in nearly 90 countries. The companys products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing.

Genzyme Biosurgery Genzymes orthopaedics European franchise comprises several novel treatments: Synvisc, Synvisc-One and MACI.

Synvisc and Synvisc-One (hylan G-F 20) are viscosupplements used to treat pain associated with knee osteoarthritis.

MACI (Matrix-induced Autologous Chrondocyte Implantation) is an autologous cartilage repair treatment for repair of articular cartilage defects in symptomatic patients. MACI has been predominantly administered in the knee joint.

Genzymes platform for innovative biomaterials also includes the Sepra franchise of products for post-surgical adhesion prevention.